Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases

doi:10.3748/wjg.v13.i5.785

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1898)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

259

HTML

1250

Figures (1-1)

200

Tables (1-4)

189

Sum=1898

Feb 7, 2007 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Feb 7, 2007; 13(5): 785-790
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.785

Table 1 Serum IGF-1, osteocalcin and PTH levels in patient groups and control group (mean ± SE)

	Control	Bilharziasis	HBV	HCV
	(n = 30)	(n = 9)	(n = 12)	(n = 29)
IGF-1 (ng/mL)	277.1 ± 12.2	94.0 ± 4.30^b	105.1± 10.3^b	230.0 ± 10.5^b
Osteocalcin (ng/mL)	5.7 ± 0.3	6.8 ± 0.66	16.5 ± 0.76^b	14.7 ± 0.54^b
PTH (ng/mL)	61.6 ± 2.7	63.3 ± 3.03	83.4 ± 4.30^b	70.1 ± 2.17^a

^aP < 0.05,

^bP < 0.01 vs control group.

Table 2 Liver function tests in different patient groups and control group (mean ± SE)

	Control	Bilharziasis	HBV	HCV
	(n = 30)	(n = 9)	(n = 12)	(n = 29)
ALT	20.5 ± 0.9	38.0 ± 6.8^a	72.6 ± 12.4^a	107.0 ± 28.1^a
(U/L)	20.5 ± 0.9	38.0 ± 6.8^a	72.6 ± 12.4^a	107.0 ± 28.1^a
AST	18.4 ± 0.8	46.0 ± 7.5^a	71.2 ± 10.8^a	120.0 ± 21.8^a
(U/L)	18.4 ± 0.8	46.0 ± 7.5^a	71.2 ± 10.8^a	120.0 ± 21.8^a
ALP	74.0 ± 9.3	82.0 ± 11.8	214.0 ± 41.2^a	165.0 ± 28.9^a
(U/L)	74.0 ± 9.3	82.0 ± 11.8	214.0 ± 41.2^a	165.0 ± 28.9^a
GGT	26.0 ± 2.1	37.6 ± 9.9	54.0 ± 1.5^a	59.9 ± 11.1^a
(U/L)	26.0 ± 2.1	37.6 ± 9.9	54.0 ± 1.5^a	59.9 ± 11.1^a
T. bilirubin	0.84 ± 0.03	0.9 ± 0.16	1.8 ± 0.20^a	1.3 ± 0.13^a
(mg/dL)	0.84 ± 0.03	0.9 ± 0.16	1.8 ± 0.20^a	1.3 ± 0.13^a
T. protein	6.9 ± 0.10	7.1 ± 0.30	6.8 ± 0.20	6.7 ± 0.10^a
(mg/dL)	6.9 ± 0.10	7.1 ± 0.30	6.8 ± 0.20	6.7 ± 0.10^a
Albumin	4.0 ± 0.06	3.9 ± 0.10	3.5 ± 0.19^a	3.6 ± 0.10^a
(mg/dL)	4.0 ± 0.06	3.9 ± 0.10	3.5 ± 0.19^a	3.6 ± 0.10^a
Prothrombin	93.0 ± 1.3	77.0 ± 4.0^a	69.0 ± 6.0^a	65.6 ± 2.50^a
(%)	93.0 ± 1.3	77.0 ± 4.0^a	69.0 ± 6.0^a	65.6 ± 2.50^a

^aP < 0.05 vs control group.

Table 3 Alterations in serum IGF-1, osteocalcin and PTH levels according to the severity of the disease from class A to C (mean ± SE)

Severity	A	B	C	LSD at 0.05
Severity	(n = 24)	(n = 22)	(n = 4)	LSD at 0.05
IGF-1	152.6^b± 7	186.8^a± 20.3	196.0^a± 36.4	32.67
(ng/mL)	152.6^b± 7	186.8^a± 20.3	196.0^a± 36.4	32.67
Osteocalcin	12.6^b± 0.9	14.6^a± 0.9	15.8^a± 1.2	1.73
(ng/mL)	12.6^b± 0.9	14.6^a± 0.9	15.8^a± 1.2	1.73
PTH	71.3^b± 3.0	70.3^b± 2.7	86.5^a± 4.3	5.36
(ng/mL)	71.3^b± 3.0	70.3^b± 2.7	86.5^a± 4.3	5.36

Within each row the means followed by different letters are significantly different. LSD: Least significance difference.

^aP < 0.05,

^bP < 0.01 vs control group.

Table 4 Effect of age and sex on serum IGF-1, osteocalcin and PTH (mean ± SE)

	Age (yr)			Sex
	3-9	10-16	P	Male	Female	P
IGF-1	153.2 ± 59.3	182.6 ± 84.5	0.268	175.2 ± 84.2	177.1 ± 58.4	0.948
(ng/mL)	153.2 ± 59.3	182.6 ± 84.5	0.268	175.2 ± 84.2	177.1 ± 58.4	0.948
Osteocalcin	13.8 ± 4.7	13.7 ± 4.2	0.941	13.1 ± 4.1	16.4^a± 4.1	0.037
(ng/mL)	13.8 ± 4.7	13.7 ± 4.2	0.941	13.1 ± 4.1	16.4^a± 4.1	0.037
PTH	71.1 ± 14.0	72.3 ± 13.8	0.786	73.1 ± 13.8	67.2 ± 13.1	0.249
(ng/mL)	71.1 ± 14.0	72.3 ± 13.8	0.786	73.1 ± 13.8	67.2 ± 13.1	0.249

^aP < 0.05 vs males.

Citation: Mahdy KA, Ahmed HH, Mannaa F, Abdel-Shaheed A. Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases. World J Gastroenterol 2007; 13(5): 785-790
URL: https://www.wjgnet.com/1007-9327/full/v13/i5/785.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i5.785